Connect with us

BUSINESS

Reliq Health Technologies Inc (OTCMKTS:RQHTF) Receives First shipment of Remote Monitoring devices

Published

on

Reliq Health Technologies Inc (OTCMKTS:RQHTF) has received the first shipment of the Remote Monitoring devices, which it had ordered a few months back. Following the delivery, the company intends to start admitting new patients. Reliq Health Technologies is a technology company that specializes in the development of highly innovative telemedicine and mobile health (mHealth) solution. The company mainly targets community-based health markets.

Several shipments expected

In a statement, Reliq Health CEO Dr. Lisa Crossley said the shipment is the first of the many deliveries of Remote Monitoring devices that are expected. She thanked the company’s customers for exercising patience in the last few months, noting that they are fully committed to delivering high quality services to patients in underserves communities.

Reliq Health signs two new contracts

In other news, the company has signed two new contracts with two home health agencies in Texas. The two contracts will enable the company to supply its iUGO Care remote patient monitoring solution to more than 4,000 patients. In addition, two clients that were recently acquired have since gone online on the iUGO Care platform.

The company has also signed an agreement with Australia’s Royal Flying Doctor Service Central Operations (RFDS) to carry out a three month pilot on the iUGO Care remote patient monitoring platform. According to Dr. Lisa, the company will be working with RFDS so as to improve the health of the people as well as the communities they live in. The program will mainly target rural and remote areas in South Australia.

Reliq Health’s decision to go into the rural areas is strategic. These remote areas are home to around half a million people, representing 2.05% of the Australian population. According to a research done by RFDS, people in remote areas of Australia are 1.6 times more like to be admitted in hospital for coronary heart complications as compared to people who live in major cities. Additionally, the report says people in remote places are 1.3 times more likely to die from heart complications. The company will therefore partner with RFDS to help and improve the lives of many patients in need.

BUSINESS

Canopy Rivers Inc (OTCMKTS:CNPOF) Will Sell Its Interests In Vert Mirabel, Tweed Tree Lot, And TerrAscend To Canopy Growth Corp (NASDAQ: CGC) For $297 Million

Published

on

Canopy Rivers Inc (OTCMKTS:CNPOF) decided to offload its interests in Vert Mirabel, Tweed Tree Lot, and TerrAscend to Canopy Growth Corp (NASDAQ: CGC). The company will use the proceeds for acquisition, investment, and merger opportunities.

Canopy Growth will pay $115 million

As per the terms of the pact, Canopy Growth will pay upfront cash of $115 million and the balance through the issue of 3.75 million common shares to Canopy Rivers. Following the transaction, Canopy Rivers will hold the largest stake in Canopy Growth. Canopy Growth will also cancel its 15.23 subordinate voting shares and 36.468 multiple voting shares in Canopy Rivers.

The CEO and President of Canopy Rivers, Narbe Alexandrian, said the transaction offers immense value to its investors and strategic flexibility besides improving cash. It also eliminates dual-class SS (share structure). He further said the company will focus on opportunities in the international cannabis market.

Chairman of JW Asset Management, Jason Wild, said he supports the transaction as a long-time investor in Canopy Rivers. Following the deal, JW Asset Management will hold a 23.9% stake in the company. Canopy Rivers is poised to capitalize on the cannabis market in the US and across the world using liquid securities and cash balances.

On completion of the transaction, the directors nominated by Canopy Growth will resign from Canopy Rivers’ board. New directors with relevant skills and expertise will be selected to manage Canopy Rivers.

The income of $82.2 million

Canopy Rivers expects to close the transaction by the end of February 2021. The company reported a significant income of $82.2 million in Q3 2021, gained from its investments in TerrAscend. It expects to maintain a strong strategic and financial position to play a vital role in the cannabis market of the US following the transaction with Canopy Growth.

Narbe said the quarter highlights include a negotiated transaction with Canopy Growth and expect to offer significant dividends to the shareholders. Its portfolio companies are maintaining momentum with the favorable regulatory reforms in the US. The company will venture into the US market at an appropriate time to clinch the emerging opportunities.

Agripharm, a Canopy Rivers portfolio company, shipped its Vape products to British Colombia in October 2020 and to Ontario in December 2020. The company also supplied Firefly Mini products to the customers in Ontario.

Continue Reading

BUSINESS

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) Establishes Digestix Bioscience Inc To Develop Pharmaceutical Compositions And Medical Devices To Treat Neoplastic Local Tumors

Published

on

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) founded an auxiliary – Digestix Bioscience. The new company will develop pharmaceutical compositions and medical devices to cure early-stage and precancerous neoplastic local tumors.

The inhibitory effects of pharmaceutical composition prevent the recurrence of adenomatous colorectal polyps, which exist in 25 to 30% of colonoscopies performed on women and men aged above 50 years. In the US, 19 million colonoscopies are conducted every year.

Cannabics holds a majority stake in Digestix

Digestix is established by Gabriel Yariv, Erez Scapa, Eitan Scapa, and Cannabics. The COO and Director of Cannabics, Gabriel Yariv, will act as CEO and interim CEO of Digestix.

The co-founder of Digestix, Eitan Scapa, said the polyps, which do not show any symptoms, can develop into colorectal cancer. Even after the removal, aggressive polyps can improve the chances of a tumor becoming cancerous. Digestix has developed a proprietary and innovative solution to mitigate the recurrence of aggressive polyps.

Scapa is specialized in liver diseases and gastroenterology. He previously managed GLDU (Gastroenterology and Liver Diseases Unit) at Asaf Harofe Medical Center. Scapa also worked as a Chairman (Helsinki Committee) at Asaf Harofe Medical Center.

Commences In-vivo studies in animal models

Cannabics commenced in-vivo trials in animal models. In this test, the company will test RCC-33 drug candidate on mice transplanted with the CCT (colorectal cancer tumor) cells. It will include the results obtained from this study in the package, which will be submitted to the US FDA.

Cannabics already completed an in-vivo study on fresh human biopsies in Israel and colorectal cancer cells using its drug candidate RCC-33. COO of Cannabics, Gabriel Yariv, said the company is excited to be at the forefront cannabinoid derived drug discovery and development. The company targets to submit a pre-clinical data package to US FDA. It is necessary to support cannabinoid-derived Drug Candidate RCC-33 to cure colorectal cancer.

Interim positive results

Cannabics achieved positive interim results from its ongoing in-vivo trial that evaluates the efficacy of RCC-33 in treating colorectal cancer in mice. According to the results, the drug candidate achieved a 25% reduction in the tumor volume in mice.

Continue Reading

BUSINESS

Halo Labs Inc (OTCMKTS:AGEEF) Enters A Share Exchange Accord To Acquire 1275111 B.C. Ltd.

Published

on

Halo Labs Inc (OTCMKTS:AGEEF) signed a deal to take over 1275111 B.C. Ltd. As per the terms of the deal, Halo Labs will issue 147,475,343 shares to buy all the outstanding and issued shares of 1275111 B.C.

1275111 B.C. developed IP related to cannabinoid purification and filtration, for which the patent is pending. Following the takeover, Halo Labs will benefit from improved economies in processing high-quality cannabis.

SVP (Operations) of Halo Labs, Josh Haddox, said the novel technology of 1275111 B.C. will help save manufacturing costs. Halo Labs expects to implement this new technology by March 2021. The deal is subject to the approval of NEO Exchange Inc and satisfying other conditions.

Mobilizes funds of CAD 2.25 million

Halo Labs will collect CAD 2.25 million through the issue of 40.9 million shares each at CAD 0.055. The shares issued through a private placement shall have a holding period of four months and one day. Halo Labs will use the proceeds from the offering for working capital needs.

Halo Labs will close the non-brokered private placement and takeover of 1275111 B.C. by January 4, 2021.

The name change to Halo Collective Inc

Following the nod of shareholders in a meeting held on December 23, 2020, the name of Halo Labs is changed to Halo Collective Inc. As a result, Halo Collective will trade under the symbol – HCANF on the OTCQX with effect from January 28, 2021. The company’s common shares will trade under the ticker – A9KM with effect from January 28, 2021.

Halo Collective plans to offer diverse products and revolutionize the cannabis sector across the world. Its innovative products include cartridges, edibles, concentrates, and quality flower. The company will cater to the needs of recreational and medical cannabis users with its innovative products. Its collective retail sales in Oregon exceeded $1 billion.

Halo Collective also completed the takeover of Eugene, Oregon-based Winberry Farms. The presence of Halo Collective expanded to include 500 dispensaries in Oregon.

Halo Collective also plans to expand its operations in Alberta, Canada, through a deal with High Tide, which operates three dispensaries offering concentrates like live resin, solventless resin, hash, and shatter.

Continue Reading

Trending Stories